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The Generation of a Library of Bromodomain Containing Protein 
Modulators Expedited by Continuous Flow Synthesis 
Paolo Filipponi, Ian R. Baxendale*[a] 
D
Abstract: A continuous flow process delivering key building-blocks 
for a series of BCP modulator libraries is reported. A dynamically 
mixed flow reactor has emerged as a pivotal technology in both 
synthetic and isolation phases enabling the processing of slurries 
and suspension whilst maintaining high productivity and reliability. 
Indeed, a key requirement of the synthesis is the rapid, large scale 
delivery of target compounds for progression into different lead 
optimization series. Accordingly, the common intermediates are 
employed herein to build a pyridazone based library (36 compounds) 
addressed at improving the lead potency and selectivity while further 
exploring the SAR of a new BCPs modulator family. 
Introduction  
The epigenetic biological network is orchestrated by several 
complex signalling pathways in which histone post translational 
modification plays a key role in regulating physiological and 
environmental stimuli in chromatin architecture modifications.1 
Different proteins and protein complexes are directly or indirectly 
involved in transcription, replication and DNA repair processes, 
physically modifying histones (writers and erasers) or 
responding to specific histone marks (readers).2 Among them, 
Bromodomain Containing Proteins (BCPs) have recently 
emerged as relevant therapeutic target with potential 
applications in oncology as well as for the treatment of 
neurological and inflammatory diseases.3 Indeed, numerous 
compounds have been disclosed to modulate bromodomain 
mediated protein-protein interactions also demonstrating the 
drugability of new BCP family members.4 However, despite the 
intense medicinal chemistry exploration that has already 
provided several promising scaffolds, additional work is required 
to define novel privileged structures for developing into 
bromodomain modulators with improved specificity and potency. 
In this context, we have recently devised a straightforward large 
scale production of key building block 1 and 2 (Figure 1).5 The 
reported flow protocol featured a dynamically mixed reactor as 
enabling technology instrumental to process slurries and 
suspensions at scale redefining, moreover, the generation of 
solids in flow from a limitation into a designed in-line operation 
directed at improving the process safety and product quality. 
The major goal of this study is the rapid delivery of quantities of 
target compounds in order to sustain an advanced medicinal 
chemistry program. Herein, along with the detailed optimization 
of the multi-gram scale synthesis of key intermediates 1 and 2, 
the synthesis of three lead development series based around 
the common 6-methyl-1-arylpyridazine nucleus (A-C, Figure 1) 
are reported and discussed. 
Figure 1. Building blocks (1, 2) selected for the generation of a focused library 
designed around three general templates A-C. 
Results and Discussion 
Process Development  
In the first phase of the study, we focused our attention on the 
process modelling and optimization of compound 1 and 2 aimed 
at developing scalable syntheses for their production. The 
selected approach for the preparation of compounds 1 and 2 
comprises two practical synthetic steps starting from a sulfuric 
acid promoted deacylation of dehydroacetic acid (DAA, 3, 
Scheme 1). The resulting triacetic acid lactone (TAL, 1) is then 
reacted in a convergent process with a diazonium salt to form 
the intermediate hydrazone 9 which is directly submitted to an 
alkaline thermal rearrangement to yield the target structure 2 
(Scheme 1). Whereas this strategy ensures acceptable reaction 
yields and batch purities at laboratory scales, it required a 
comprehensive re-optimisation in order to cope with several 
processing and isolation issues which emerged upon scaling-up 
the reactions. To translate the selected synthetic sequence into 
a flow-based process,6 each step in the synthesis of compound 
2 was individually analysed and optimised. 
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Scheme 1. Synthetic strategy adopted for the preparation of 4-hydroxy-6-
methyl-2H-pyran-2-one (TAL, 1) and 1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxylic acid (2). 
Deacylation of DAA (3) was typically performed as a batch 
process by dissolving the compound in 90% H2SO4 at a 
concentration of 3.7 M. The solution was then heated at 130 °C 
for 15-30 min, cooled and poured into 2.5 volumes of iced water. 
The mixture was stirred vigorously for 10-15 minutes and the 
resulting suspension filtered and dried. The desired TAL product 
(1) was obtained in variable isolated yields ranging from 68% to 
80%. With the aim of translating the reaction to flow we directed 
our initial evaluation efforts at appraising the sulfuric acid 
concentration and heating temperature on the yield. 
 
We immediately found that the amount of water present in the 
reaction mixture had a critical impact on determining the product 
speciation. Using a high water content changed the reaction 
outcome allowing two alternative products to be isolated and 
characterised (6, 7 Figure 2). 
 
Figure 2. Principal by-products isolated in the synthesis of TAL (1): 3,5-
dimethyl-4-pyrone (6) and 2,6-dimethyl-4-oxo-4H-pyran-3-carboxylic acid (7). 
The symmetrical 3,5-dimethyl-4-pyrone (6) was recovered as the 
main component when performing the reaction in dilute (10, 25, 
60 wt%), hot (>100 °C) sulfuric acid. A reduction in the 
percentage of water corresponded to an increase in the 
presence of the parent lactone; 2,6-dimethyl-4-oxo-4H-pyran-3-
carboxylic acid (7) (Table 1, entries 1-3). A simple trend was 
also determined for temperature; experiments demonstrated that 
a deviation from the optimal setting (130 °C) translated to a 
decrease in yield and prolonged reaction times (Table 1, entries 
9-13). 
 
However, the principle reason for low isolated yields was 
determined to be inefficiencies in the workup sequence. This 
was demonstrated by the significant differences between the 
final isolated and 1H-NMR determined yield (Table 1, Entries 4 
and 5).  
Interestingly we found no discernible decrease in the isolated 
yield when varying the volume of water used in the quench step 
nor when increasing the incubation time before filtration (Table 
2; entries 1-5). However, an increase in the amount of water 
used in the quench phase did translate to a beneficial effect on 
the quality of the precipitate produced. Using 7.5-10 volumes of 
water was found to be optimal producing a readily filtered white 
flocculent solid. By comparison decreasing the amount of water 
had a negative impact producing a solid which rapidly 
agglutinates and became extremely difficult to filter and dry. This 
immediately became a process limiting issue as the working 
scale increased. We also noted the quench temperature 
required careful regulation as at elevated temperatures >15 °C 
as generated by the very exothermic mixing side reactions 
occurred which affected the yield and purity (Table 2; entries 6-
7). This was particularly noticeable at higher reaction scales 
were appreciable off gassing was noted presumably from 
hydrolysis of the product and its subsequent decarboxylation 
(Table 2, entry 7).  
 
Table 1. Evaluation of the sulphuric acid concentration and temperature 
effects on the deacylation yield.
[a]
 
Entry H2SO4  Temp.(°C)  H-NMR yield
[b]
 Isolated 
Yield (1) 
1 6 7 
1 25% reflux - 90% - - 
2 10% reflux - >90% - - 
3 60% 110 55% - 10% 28% 
4 75% 130 - - - 41% 
5 80% 130 - - - 60% 
6 90% 130 - - - 68% 
7 92.5% 130 91% - 9% 79% 
8 >95% 130 94% - 6% 81% 
9 98%
[c]
 130 100% - 0% - 
10 98%
[c]
 110 76% - 0% - 
11 >95% 80 - - - 63%
[d]
 
12 >95% 150 - - - 66% 
13 >95% 180 - - - 55% 
[a] Reaction conditions: DAA (3, 15 mmol, 3.7 M), 15 min. [b] Determined 
analysis of a crude aliquot dissolved in D2SO4. [c] Reaction performed in 
D2SO4. [d] Yield referred to 4 h reaction time. 
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Table 2. Evaluation of the water volume on quenching efficiency
[a]
 
Entry H2O volumes Incubation time Isolated yield 
1 2.5 2 h 80%
[b]
 
2 5 2 h 82%
[b]
 
3 7.5 2 h 79%
[b]
 
4 10 2 h 79%
[b]
 
5 10 12 h 78%
[b]
 
6 5 2 h 54%
[c]
 
7 5 2 h 47%
[d]
 
[a] Reaction conditions: DAA (3) (15 mmol, 3.7 M), H2SO4 >95%, 130 °C, 
15 min. [b] Quenching: the crude mixture was poured in iced water 
maintained at 0-5 °C. [c] Addition of the crude mixture to ambient 
temperature water. [d] Reaction conditions: DAA (3) (4 mol, 3.7 M), H2SO4 
>95%, 130 °C, 15 min. Addition of the crude mixture to 5 volumes of iced 
water over 10 minutes, internal temperature reaches 26 °C. 
 
We concluded from our explorative study that the use of 
concentrated (>95%) sulfuric acid at high temperature 
(130 °C) were key reaction attributes leading to excellent 
conversion. Furthermore accurate control of the quenching 
parameters like temperature and mixing efficiency (including 
the amount of water) emerged as critical aspects in ensuring 
a high isolated yield and contributed significantly to the overall 
success of the process. Based upon these considerations we 
envisaged to gain both operational safety and product 
processing benefits by implementation of flow technologies, 
gaining profitable in terms of containment, heat transfer 
(exotherm control) and improved mixing in both the synthetic 
and quenching steps. We therefore investigated the use of a 
dynamically mixed flow reactor selected for its ability to 
handle suspensions (Figure 3).7 
 
Figure 3. The AM Technology Coflore® ATR. The reactor has ten 
interconnected tubes with a total reactor volume of 1 L. All pipes are 
equipped with an internal dynamic mixer which generates a turbulent flow 
stream through lateral shacking. 
Accordingly, after demonstrating the prolonged stability of the 
DAA (3) starting material in H2SO4 (>95%) at ambient 
temperature, a 2 M stock solution was prepared and pumped 
using a Vapourtec MedChem module into two parallel 
configured polar bear flow synthesisers equipped with PTFE coil 
reactors (volume 52 mL, temperature 130 °C). The outflows from 
the twin reactors (8 mL/min) were combined at a Teflon T-piece 
and the stream directed into the first chamber of the Coflore 
ATR reactor (volume 100 mL, agitator frequency 4 Hz, 
temperature 5-10 °C). A secondary input of water (10 °C, 
delivered at 60 mL/min equating to 7.5 volumes) was added at 
right angles via a side connector of the Coflore agitated chamber. 
The precipitate that formed was processed through the agitated 
reactor and dispensed onto a glass sintered vacuum suction 
plate to facilitate filtration (Scheme 2). The process was run 
continuously with periodic removal of the filtered material 
delivering a high productivity (116 g/h dry mass, 96% yield).  
Therefore, whilst minimizing the safety issues of handling 
concentrated sulfuric acid, the devised flow configuration also 
ensured a nearly quantitative recovering of the TAL easily 
isolated by filtration as an off white, fine powder.  
 
 
Scheme 2. Continuous flow set up for the synthesis and isolation of TAL (1). 
Our next challenge was the optimization and scale up of the 
synthesis of pyridazone 2 (Scheme 1). The selected approach 
involved a multi-step sequence comprising a base catalyzed 
addition of lactone 1 (0.2 M) with a fleshly generated aryl 
diazonium salt 4. In batch the resulting suspension was heated 
at reflux for three hours to promote the intramolecular cyclisation 
to the rearranged hydrazone 5. The dark red homogenous 
mixture thus obtained was treated with activated charcoal and 
filtered. The filtrate was then acidified with concentrated HCl 
which induced precipitation of final product 2. Again, performing 
this sequence at scale gave rise to several problems mainly 
related to processing times and safety.  
For example, the initial coupling reaction (1+4→5) is 
strongly exothermic (mixing acid/base solutions) and therefore 
requires the dropwise addition of the diazonium salt solution 
resulting in prolonged reaction times. This was additionally 
problematic as certain diazonium salts proved unstable and 
degraded over time to yield varying amounts of the 
corresponding phenols. Scaling up also increases the necessary 
addition time and as a consequence gives higher levels of 
impurity. A further issue was found upon scale up relating to the 
selection of the alkali carbonate base which promoted the 
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rearrangement. At scale copious CO2 evolution combined with 
the insolubility of the hydrazone intermediate 5, results in 
significant foaming with deleterious effects on mixing efficiency 
which impacted upon the reaction time. We thus designed a 
multistep flow process again based upon the use of the ATR 
reactor selected for its ability to process slurries and suspension 
whilst ensuring enhanced mixing and isothermal control.  
 
Diazonium salt coupling 
The diazonium species 4 was prepared in situ as follows: A 
solution of NaNO2 in water (0.4 M) was mixed at a T-connector 
with 4-bromoaniline (0.33 M) dissolved in aqueous HCl (0.93 M) 
and the combined flow stream then progressed through a 20 mL 
coil reactor (Scheme 3). This simple flow configuration worked 
well over a wide range of temperature (-10 °C to 25 °C) 
delivering a continuous stream of the desired diazonium salt 4 in 
quantitative conversion. The corresponding secondary input, a 
solution of TAL (1) was prepared by the addition of a 
substoichiometric quantity of K2CO3 (0.65 equivalents) which 
proved efficient at solubilizing 1 in an aqueous media. The base 
also sufficiently raised the pH to catalyze the subsequent 
diazonium coupling step (1+4→5). Therefore the streams of TAL 
(1) and diazonium salt 4 could be blended together within the 
confines of the first 100 mL ATR reactor chamber (maintained at 
rt). The intermediate 5 could be easily processed under dynamic 
mixing with a residence time of 10 minutes. The outflow 
suspension, if required, could be continuously filtered allowing 
isolation of compound 5 in almost quantitative yield and high 
purity as a fine yellow powder. 
It is worthy of note that in comparison to the original batch 
procedure these flow conditions are much milder. As a 
consequence we encountered less degradation of the 
intermediate diazonium 4 (phenol formation) thereby allowing its 
relative stoichiometry to be reduced (1.1 equiv. cf 2.5 equiv. in 
batch). In addition the CO2 evolution and associated foaming 
issues highly problematic at scale in batch were also diminished 
increasing the efficiency of the reaction. 
 
Scheme 3. Continuous flow set up for the synthesis and isolation of 1-(4-
bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylic acid (2). 
Although the optimized conditions proved highly beneficial for 
the first derivatization stage, the subsequent intramolecular 
cyclization (5→2) required more basic conditions. Therefore a 
successive injection of K2CO3 solution (1.5 M) was used to 
promote the conversion of hydrazone 5 to the final pyridazone 2. 
In the final configuration the flow of feed 5 was mixed with a 
solution of K2CO3 (1.5 M) pumped at 5 mL/min. The combined 
flow stream was then processed through a further 8 
interconnected ATR chambers (temperature maintained at 85 
°C) corresponding to a total residence time of approx. 53 
minutes (Scheme 3). 
In batch we had found that isolation of the final material 2 
necessitated treatment of the crude product solution with 
activated charcoal followed by acidification and filtration of the 
resulting solid. However, it was determined that the charcoal 
cleanup step as well as being a laborious operation was 
significantly less effective at scale, the final material isolated was 
still often contaminated by an dark red oily residue which 
furthermore affected the filtration process. We thus decided to 
implement an on-line extraction by using the final ATR reactor 
chamber. A flow stream of toluene pumped at 15 mL/min was 
added and the biphasic mixture processed through the final 100 
mL dynamically agitated tube (residence time 3.3 min). The 
outflow was collected into a settling tank (1.2 L): an extraction 
line continuously removed the organic phase which was directed 
to waste. The lower aqueous fraction was periodically drained, 
acidified with HCl 37% and finally filtered. The recovered pale 
tan solid was dried under vacuum to yield the desired pure 
product 2 in an overall 73%. This multistep sequence had a 
productivity of 9.6 g/h. 
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Figure 3. A series compounds synthesized by reacting TAL (1) with different 
substituted diazonium salts. 
Following the successful development of the flow process to 
prepare key building block 2 we were able to utilise the same 
reactor to generate a small derivative library (Figure 3). 
Pyranone 1 was therefore used as the starting material for the 
preparation of 13 materials 8-14 characterised by different 
substituents at the phenyl moiety all isolated in good yield by 
means of acidification and filtration of the crude aqueous 
mixtures as described above.  
 
Library construction 
Our preliminary medicinal chemistry screening had identified the 
pyridazone framework 2 as a promising scaffold for evolution in 
a more advanced lead optimization study. In particular, its 
versatile structure was highly attractive due to its potential for 
late stage modifications providing different sites for chemical 
manipulation. Accordingly, we report here two example lead 
development series (B and C, Figure 1) which generated 
compounds readily available for biological testing. It should be 
highlighted that the library preparation was rapidly progressed 
due to bulk quantities of the starting material 2 as furnished from 
the flow chemistry scale up described above. 
 
The synthesis of the amide library B required the preliminary 
activation of the carboxylic acid moiety. This was easily 
achieved by treating 2 with 1,1’-carbonyldiimidazole (CDI) in 
MeCN for 1 h. The active amide was then mixed with the desired 
amine and the reaction stirred overnight at ambient temperature. 
Several of the products formed a precipitate allowing the product 
to be directly filtered. The solid was then easily purified by two 
consecutive washings with MeCN and Et2O respectively. This 
simple work-up procedure led to the isolation of pure products 
15-18, 20 in yields ranging from 42% to 77%. In each case 
additional material could also be recovered by flash 
chromatography purification of the filtrate. Other compounds 
gave negligible precipitation, these products 19, 21-23 required 
direct silica column purification but again resulted in high yields 
of the coupled products. As depicted in Figure 4, this synthetic 
method proved effective for a wide range of amines allowing for 
the synthesis of both aromatic and aliphatic amides with variable 
length side chains. 
 
In order to gain additional insight in the structure activity 
relationship of this new class of BCPs modulators and in line 
with a generally adopted medicinal chemistry strategy, we 
further designed a series of constrained derivatives (C, Figure 1). 
In particular, for the better understanding of the influence of the 
amide orientation on both affinity and selectivity, we planned to 
lock the -ketoamide moiety into a pyrazole structure. In this way, 
we achieved a selective functionalization at the N-1 position of 
the pyrazole portion delivering additional samples (27-31, 
Scheme 4) with a defined hydrophobic side chain orientation.  
  
The synthesis of the fused pyrazolo[4,3-c]pyridazine motif 
initially required the preparation of the more reactive thioxo ester 
derivative 25. Accordingly, after the esterification of the starting 
material 2, the new intermediate 24 was treated with Lawesson’s 
reagent in toluene. For the preparation of aryl derivatives 27-28, 
the resulting compound 25 was reacted with different substituted 
hydrazines under microwave irradiation at 150 °C for 2 h 
(Method A, Scheme 4). Despite the forcing reaction conditions 
only moderate conversions could be achieved. However, the 
efficiency and levels of automation derived from the use of a 
microwave synthesizer coupled with robot arm, resulted in a 
general reduction in processing time when compared with the 
batch procedure. For example, an essentially identical yield was 
obtained in preparing derivative 28a by heating the reaction 
mixture at reflux for 48 h. 
 
 
Figure 4. B series amide derivatives prepared starting from the intermediate 2. 
Alternatively the benzyl and alkyl compounds 29-31 could be 
synthesized by initial condensation of the thio derivative 25 with 
hydrazine in good overall isolated yield (Method B, Scheme 4). 
The subsequent N-functionalization of 26 with an alkyl bromide 
emerged as a valuable synthetic approach yielding compounds 
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29-31 in moderate to excellent yield. The compounds could be 
easily purified by column chromatography. This again 
demonstrated the versatility of the scaffold to rapid and selective 
structural modification. 
 
Scheme 4. Synthetic strategy adopted for the preparation of C series 
pyrazolo[4,3-c]pyridazine derivatives 27-31.  
Conclusions 
Over the last year, the modulation of bromodomains mediated 
protein-protein interactions have emerged as one of the most 
promising intervention area for epigenetic therapies. The novelty 
and potential of these biological targets have stimulated intense 
research activity with many promising results particularly in 
oncology. However, consistently with the multi-regulatory 
behaviour of various bromodomains and BCPs, the 
comprehensive understanding of their physio-pathological role 
still demands the continuous development of new, potent and 
selective pharmacological tools. Accordingly, we have 
developed a multi-gram scale flow synthesis of several building 
blocks (1, 2, 8-14, Figure 1) instrumental for the rapid synthesis 
of focused BCPs modulators libraries. The use of flow chemistry 
technologies has strongly impacted the research outcomes in 
terms of time, cost and manpower. Indeed, the devised process 
has delivered sufficient benefits to justify the initial development 
efforts enabling the continuous production of large quantities of 
target compounds without additional scale-up and re-
optimization studies. The large scale availability as well as the 
synthetic versatility of the produced building blocks allowed for 
an accelerated generation of a compound collection based upon 
the pyridazinone scaffold (A-C, Figure 1). These new BCPs 
modulators were specifically designed to provide insight on the 
hydrophobic moieties influence on both potency and selectivity. 
We are confident therefore that their biological assays combined 
with the chemical diversity explored, will contribute to extend 
their SAR and pharmacological profile, and, in general, will 
support the ongoing research efforts geared toward the better 
understanding of the BCPs biology and therapeutic potential. 
Experimental Section 
Materials and Methods 
All solvents were purchased from Fisher Scientific and used without 
further purification. Reagents were purchased from Alfa Aesar or Sigma 
Aldrich and used as received. Flow reactions were performed either on a 
Vapourtec (R-series and E-series) or a Polar Bear plus Flow™ or AM 
Technology Coflore® modules equipped with standard PTFE tubing (3.2 
x 1.5 mm, o.d. x i.d) and connectors.1H-NMR and 13C-NMR spectra were 
recorded on Bruker Avance-400 instrument and are reported relative to 
CDCl3 (δ 7.26 ppm and δ 77.2 ppm respectively) or DMSO-d6 (δ 2.50 
ppm and δ 39.5 ppm respectively). Data for 1H-NMR are reported as 
follows: chemical shift (δ/ ppm) (integration, multiplicity, coupling constant 
(Hz)). Multiplicities are reported as follows: s = singlet, d = doublet, dd = 
doublet of doublets, ddd = doublet of doublet of doublets, dddd = doublet 
of doublet of doublet of doublets, t = triplet, q = quartet, m = multiplet, br. 
s = broad singlet. Data for 13C-NMR are reported in terms of chemical 
shift (δ/ ppm) and multiplicity (C, CH, CH2 or CH3). Data for 
19F-NMR 
were recorded on the above instrument at a frequency of 376 MHz using 
DMSO as external standard. IR spectra were obtained by use of a Perkin 
Elmer RX1 spectrometer (neat, ATR sampling) with the intensities of the 
characteristic signals being reported as weak (w, <51% of tallest signal), 
medium (m, 51-70% of tallest signal) or strong (s, >71% of tallest signal). 
Low and high resolution mass spectrometry were performed using the 
indicated techniques on either Waters LCT Premier XE or Waters TQD 
instruments equipped with Acquity UPLC and a lock-mass electrospray 
ion source. For accurate mass measurements the deviation from the 
calculated formula is reported in mDa. 
Multigram-scale flow procedures 
4-hydroxy-6-methyl-2H-pyran-2-one (TAL, 1). 
Two solutions of 3-acetyl-4-hydroxy-6-methyl-2H-pyran-2-one (3) (2 M) 
were individually pumped at 4 mL/min into two parallel coil reactors (52 
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ml) heated at 130 °C. The combined crude outflows fed, along with a 
stream of water (60 mL/min), a 100 mL Coflore® ATR reactor chamber 
cooled at 10 °C. The resulting suspension was filtered and the pale 
yellow solid dried under vacuum obtaining the pure title compound 1 in 
92% yield. 
Mp: 185.6 °C (decomposed). 1H NMR (400 MHz, DMSO-d6) δ 11.61 (s, 
1H), 5.96 (s, 1H), 5.21 (s, 1H), 2.16 (s, 3H). 13C NMR (101 MHz, DMSO-
d6) δ 171.0 (C), 164.4 (C), 163.8 (C), 100.6 (CH), 88.6 (CH), 19.9 (CH3). 
IR (neat): 2362.4 (w), 1658.1 (m), 1618.2 (m), 1538.5 (m), 1492.62 (m), 
1255.2 (s), 1149.2 (m), 985.2 (s), 878.0 (m), 833.0 (s), 812.21 (s), 729.2 
(m), 635.3 (m), 591.4 (s), 526.2 (s), 497.8 (s) cm-1. LC-MS (ESI): 125.0 
(M-H); HRMS (ESI): calculated for C6H7O3 127.0395, found 127.0389 
(M+H, Δ = -0.6 mDa). 
1-(4-bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 2. 
Two solutions pumped at 2.5 mL/min were mixed in a T-piece before 
entering in a coil reactor (20 mL) cooled at 10 °C: one containing NaNO2 
0.4 M and the second containing 4-bromoaniline (0.33 M) solubilised in 
aqueous HCl (0.93 M). The outflow was combined with a stream of 1 
(0.15 M) dissolved in K2CO3(aq) (0.098 M) and pumped at 5 mL/min. The 
resulting mixture was reacted at room temperature in the first chamber of 
the ATR reactor. A second stream of K2CO3(aq) 1.5 M was thus injected in 
the reactor at 5 mL/min and main stream processed into eight 100 mL 
dynamically mixed pipes heated at 85 °C. As the crude mixture enters 
the last reactor chamber it was mixed with a stream of toluene pumped at 
15 mL/min. The biphasic solution that exited the reactor was separated. 
The water layer was acidified with HCl 37% and the suspension obtained 
filtered. The pale orange solid recovered was dried under reduced 
pressure obtaining the pure title compound 2 in 73% yield. 
Mp: 214.0 °C (decomposed). 1H NMR (400 MHz, DMSO-d6) δ 15.55 (brs, 
1H), 7.85 (d, J = 8.4 Hz, 2H), 7.61 (d, J= 8.4 Hz, 2H), 7.12 (s, 1H), 2.25 
(s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.3 (C), 163.1 (C), 156.0 (C), 
143.0 (C), 141.5 (C), 133.1 (2CH), 129.1 (CH), 124.0 (C), 120.6 (CH), 
20.9 (CH3). IR (neat):1727.7 (m), 1566.3 (m), 1485.4 (s), 1337.9 (m), 
1284.2 (m), 1218.8 (s), 1067.6 (s), 1015.6 (s), 909.7 (m), 839.7 (s), 794.1 
(m), 738.1 (m), 641.0 (m) cm-1. LC-MS (ESI): 307.1 (M-H). HRMS (ESI): 
calculated for C12H10N2O3Br 308.9875, found 308.9882 (M+H, Δ = +0.7 
mDa).  
Compound library building 
General flow procedure for the preparation of A derivatives 8-14. 
Compounds 8-14 were prepared following the flow procedure as 
described for compound 2 above. 
1-(4-Chlorophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 8a, 86 % 
Compound description: white solid. Mp: 216.0 - 217.2 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 15.57 (brs, 1H), 7.72 (d, J = 9.6 Hz, 2H), 
7.68 (d, J = 9.6 Hz, 2H), 7.13 (s, 1H), 2.25 (s, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 171.3 (C), 163.1 (C), 156.0 (C), 143.0 (C), 141.1 (C), 135.3 
(C), 130.2 (CH), 128.8 (CH), 120.6 (CH), 20.9 (CH3). IR (neat):3046.5 (w), 
1730.6 (s), 1619.5 (m), 1562.6 (m), 1485.4 (s), 1338.8 (m), 1288.1 (s), 
1220.0 (s), 1085.2 (s), 1017.4 (s), 909.9 (m), 841.7 (s), 797.8 (m), 745.0 
(m), 645.7 (m) cm-1. LC-MS (ESI): 263.2 (M-H). HRMS (ESI): calculated 
for C12H10N2O3Cl 265.0380, found 265.0392 (M+H, Δ = +1.2 mDa). 
1-(4-Carboxyphenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 8b, 58 %. 
Compound description: pale orange solid. Mp: 243 °C (decomposed). 1H 
NMR (400 MHz, DMSO-d6) δ 15.35 (br s, 1H), 13.53 (brs, 1H), 8.16 (d, 
J= 8.5 Hz, 2H), 7.76 (d, J= 8.5 Hz, 2H), 7.12 (d, J = 0.8 Hz, 1H), 2.27 (d, 
J = 0.8 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.2 (C), 166.7 (C), 
163.1 (C), 155.7 (C), 145.4 (C), 143.1 (C), 132.8 (C), 131.1 (CH), 127.3 
(CH), 120.7 (CH), 20.9 (CH3). IR (neat): 2300-3200 (br, m), 1702.0 (s), 
1594.6 (s), 1445.1 (s), 1413.5 (s), 1284.6 (s), 1247.5 (s), 1100.3 (m), 
938.0 (m), 878.6 (m), 771.6 (m), 698.4 (s) cm-1. LC-MS (ESI): 273.2 (M-
H). HRMS (ESI): calculated for C13H11N2O5 275.0668, found 275.0663 
(M+H, Δ = -0.5 mDa). 
1-(3-Bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 9a, 77 %. 
Compound description: off white solid. Mp: 222.6 °C (decomposed). 1H 
NMR (400 MHz, DMSO-d6) δ 15.55 (brs, 1H), 7.96 (t, J = 2.0 Hz, 1H), 
7.85 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.69 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 
7.59 (t, J = 8.0 Hz, 1H), 7.12 (d, J= 0.7 Hz, 1H), 2.27 (d, J= 0.7 Hz, 3H). 
13C NMR (101 MHz, DMSO-d6) δ 171.3 (C), 163.1 (C), 156.0 (C), 143.3 
(C), 143.0 (C), 133.7 (CH), 132.0 (CH), 129.9 (CH), 126.2 (CH), 122.4 
(C), 120.6 (CH), 20.9 (CH3). IR (neat): 3073.9 (w), 1735.9 (s), 1606.4 (m), 
1580.9 (s), 1515.1 (s), 1464.1 (s), 1417.1 (s), 1265.3 (s), 1107.0 (m), 
887.9 (m), 802.0 (s), 641.6 (s) cm-1. LC-MS (ESI): 307.1 (M-H). HRMS 
(ESI): calculated for C12H10N2O3Br 308.9875, found 308.9871 (M+H, Δ = 
-0.4 mDa). 
1-(3-Chlorophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 9b, 71 %. 
Compound description: white solid. Mp: 194.9 - 196.2 °C. 1H NMR (400 
MHz, DMSO-d6) δ 15.54 (brs, 1H), 7.86–7.83 (m, 1H), 7.74–7.70 (m, 1H), 
7.69–7.62 (m, 2H), 7.12 (d, J= 0.8 Hz, 1H), 2.27 (d, J= 0.8 Hz, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ 171.3 (C), 163.1 (C), 155.9 (C), 143.3 (C), 
143.0 (C), 134.2 (C), 131.8 (CH), 130.9 (CH), 127.1 (CH), 125.8 (CH), 
120.6 (CH), 20.8 (CH3). IR (neat):1737.9 (s), 1610.4 (m), 1584.6 (s), 
1504.4 (s), 1470.0 (s), 1110.7 (m), 965.4 (m), 892.1 (s), 789.7 (s), 671.8 
(s), 644.1 (s) cm-1. LC-MS (ESI): 263.2 (M-H). HRMS (ESI): calculated 
for C12H10N2O3Cl 265.0380, found 265.0384 (M+H, Δ = +0.4 mDa). 
1-(3-Fluorophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 9c, 68 %. 
Compound description: white solid. Mp: 106.2 - 108.4 °C. 1H NMR (400 
MHz, DMSO-d6) δ 15.53 (brs, 1H), 7.73 – 7.62 (m, 2H), 7.56 – 7.48 (m, 
2H), 7.12 (d, J= 0.8 Hz, 1H), 2.27 (d, J= 0.8 Hz, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 171.2 (C), 163.1 (C), 162.3 (d, J = 247.5 Hz, CF), 155.9 (C), 
143.3 (d, J = 10.2 Hz, C), 143.1 (C), 132.0 (d, J = 9.0 Hz, CH), 123.4 (d, 
J = 3.3 Hz, CH), 120.5 (CH), 117.9 (d, J = 20.8 Hz, CH), 114.8 (d, J = 
24.8 Hz, CH), 20.8 (CH3). 
19F NMR (376 MHz, DMSO-d6) δ -110.44 (s). 
IR (neat): 3067.8 (w), 1714.0 (m), 1598.9 (s), 1485.1 (s), 1418.3 (m), 
1342.4 (m), 1290.9 (m), 1210.4 (s), 1196.1 (s), 1038.1 (m), 896.5 (s), 
881.4 (s), 771.9 (s), 697.5 (m), 647.6 cm-1. LC-MS (ESI): 247.2 (M-H). 
HRMS (ESI): calculated for C12H10N2O3F 249.0675, found 249.0679 
(M+H, Δ = +0.4 mDa). 
1-(3-Methoxyphenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 9d, 86 %. 
Compound description: dark brown solid. Mp: 186.2 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 15.71 (brs, 1H), 7.53 (t, J = 8.1 Hz, 1H), 
7.26 (t, J = 2.2 Hz, 1H), 7.15 - 7.22 (m, 2H), 7.14 (d, J = 0.9 Hz, 1H), 3.82 
(s, 3H), 2.27 (d, J = 0.7 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.4 
(C), 163.1 (C), 160.4 (C), 156.1 (C), 143.3 (C), 142.5 (C), 131.0 (CH), 
120.6 (CH), 118.8 (CH), 116.6 (CH), 112.5 (CH), 56.1 (CH3), 20.8 (CH3). 
IR (neat): 1738.3 (s), 1605.3 (s), 1515.3 (s), 1475.7 (s), 1434.4 (s), 
1236.8 (s), 1019.6 (s), 983.8 (s), 861.9 (s), 797.1 (s), 689.8 (m) cm-1. LC-
MS (ESI): 259.2 (M-H). HRMS (ESI): calculated for C13H13N2O4 261.0875, 
found 261.0874 (M+H, Δ = -0.1 mDa). 
1-(m-tolyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-carboxylic acid, 
9e, 79 %. 
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Compound description: cream solid. Mp: 204.4 - 205.1 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 15.74 (brs, 1H), 7.55 – 7.48 (m, 1H), 
7.46 – 7.39 (m, 3H), 7.14 (d, J = 0.8 Hz, 1H), 2.41 (s, 3H), 2.26 (d, J = 
0.8 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.3 (C), 163.1 (C), 156.1 
(C), 142.6 (C), 142.3 (C), 140.1 (C), 131.3 (CH), 129.9 (CH), 127.1 (CH), 
123.7 (CH), 120.7 (CH), 21.2 (CH3), 20.9 (CH3). IR (neat): 3065.5 (w), 
1732.1 (m), 1608.3 (m), 1514.1 (s), 1471.0 (s), 1440.4 (s), 1279.1 (s), 
1221.1 (s), 1102.5 (m), 999.5 (s), 888.8 (s), 801.3 (s), 643.1 (s) cm-1. LC-
MS (ESI): 243.2 (M-H). HRMS (ESI): calculated for C13H13N2O3 245.0926, 
found 245.0935 (M+H, Δ = +0.9 mDa). 
1-(3-(trifluoromethyl)phenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-
3-carboxylic acid, 9f, 68 %. 
Compound description: orange solid. Mp: 129.3 - 130.4 °C. 1H NMR (400 
MHz, DMSO-d6) δ 15.52 (brs, 1H), 8.16 (s, 1H), 7.97-8.05 (m, 2H), 7.88 
(t, J = 7.9 Hz, 1H), 7.13 (s, 1H), 2.26 (s, 3H). 13C NMR (101 MHz, DMSO-
d6) δ 171.3 (C), 163.1 (C), 156.0 (C), 143.2 (C), 131.6 (CH), 131.3 (CH), 
130.8 (q, J = 33 Hz), 127.6 (q, J = 4 Hz, CH), 124.2 (q, J = 4 Hz, CH), 
123.9 (q, J = 271 Hz, CF3), 120.6 (CH), 20.9 (CH3). 
19F NMR (376 MHz, 
DMSO-d6) δ -61.2 (s). IR (neat): 1738.0 (m), 1609.1 (m), 1475.3 (s), 
1439.9 (s), 1325.1 (s), 1165.7 (s), 1129.4 (s), 1103.1 (s), 1068.1 (s), 
819.2 (s), 702.8 (s), 618.5 (s) cm-1. LC-MS (ESI): 297.2 (M-H). HRMS 
(ESI): calculated for C13H10N2O3F3 299.0644, found 299.0649 (M+H, Δ = 
+0.5 mDa). 
1-(2-methyl-5-nitrophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 10, 66 %. 
Compound description: cream solid. Mp: 200.1 - 201.5 °C. 1H NMR (400 
MHz, DMSO-d6) δ 15.42 (brs, 1H), 8.61 (d, J = 2.4 Hz, 1H), 8.40 (dd, J = 
8.5, 2.5 Hz, 1H), 7.81 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 0.9 Hz, 1H), 2.20 (s, 
3H), 2.19 (d, J = 0.7 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.3 (C), 
163.0 (C), 156.1 (C), 146.8 (C), 144.0 (C), 143.3 (C), 141.2 (C), 133.3 
(CH), 125.7 (CH), 123.2 (CH), 120.6 (CH), 20.1 (CH3), 17.3 (CH3). IR 
(neat): 1732.0 (s), 1596.8 (m), 1527.5 (m), 1443.5 (s), 1347.5 (s), 1284.4 
(s), 1077.1 (m), 892.2 (m), 840.4 (m), 737.6 (s), 645.5 (m) cm-1. LC-MS 
(ESI): 288.2 (M-H). HRMS (ESI): calculated for C13H12N3O5 290.0777, 
found 290.0776 (M+H, Δ = -0.1 mDa). 
1-(2,4-Difluorophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 11, 65 %. 
Compound description: pale brown solid. Mp: 194.0 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 15.08 (s, 1H), 7.89 (td, J = 8.9, 5.8 Hz, 
1H), 7.71 (ddd, J = 10.4, 8.9, 2.8 Hz, 1H), 7.40 (dddd, J = 9.1, 8.1, 2.8, 
1.4 Hz, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.8 (C), 
163.5 (dd, J = 253.0, 12.1 Hz, CF),163.1 (C), 156.9 (dd, J = 253.0, 12.1 
Hz, CF), 156.1 (C), 145.1 (C), 131.0 (d, J = 10.6 Hz, CH), 126.3 (dd, J = 
12.7, 4.1 Hz, C), 120.2 (CH), 113.5 (dd, J = 23.0, 3.7 Hz, CH), 106.3 (dd, 
J = 27.6, 23.3 Hz, CH), 19.9 (CH3). 
19F NMR (376 MHz, DMSO-d6) δ -
104.93 (d, J = 9.0 Hz), -118.21 (d, J = 9.0 Hz). IR (neat): 1732.4 (s), 
1599.4 (s), 1502.8 (s), 1470.9 (s), 1272.8 (m), 1251.9 (m), 1148.6 (m), 
1091.0 (m), 966.0 (m), 940.0 (m), 893.9 (m), 859.7 (s), 739.8 (m), 611.3 
(s) cm-1. LC-MS (ESI): 265.2 (M-H). HRMS (ESI): calculated for 
C12H9N2O3F2 267.0581, found 267.0584 (M+H, Δ = +0.3 mDa). 
1-(4-Chloro-2-nitrophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 12, 67 %. 
Compound description: tan solid. Mp: 221.2 - 221.8 °C (decomposed). 1H 
NMR (400 MHz, DMSO-d6) δ 15.18 (brs, 1H), 8.52 (d, J = 2.4 Hz, 1H), 
8.17 (dd, J = 8.5, 2.4 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.06 (d, J = 0.8 
Hz, 1H), 2.27 (d, J = 0.8 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.5 
(C), 163.0 (C), 155.9 (C), 145.4 (C), 144.9 (C), 136.8 (C), 135.9 (CH), 
133.4 (C), 131.8 (CH), 127.0 (CH), 120.2 (CH), 20.2 (CH3). IR 
(neat):1732.3 (s), 1596.7 (m), 1533.5 (s), 1515.1 (s), 1475.5 (s), 1342.4 
(s), 1297.4 (m), 1154.2 (m), 1119.0 (m), 969.4 (m), 866.4 (s), 846.5 (m), 
762.2 (s) cm-1. LC-MS (ESI): 308.2 (M-H). HRMS (ESI): calculated for 
C12H9N3O5Cl 310.0231, found 310.0228 (M+H, Δ = -0.3 mDa). 
1-(3-Chloro-4-fluorophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 13, 80 %. 
Compound description: cream solid. Mp: 214.1 - 214.9 °C. 1H NMR (400 
MHz, DMSO-d6) δ 15.46 (brs, 1H), 8.05 (dd, J = 6.6, 2.4 Hz, 1H), 7.85 – 
7.51 (m, 2H), 7.10 (d, J = 0.9 Hz, 1H), 2.26 (s, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 171.2 (C), 163.1 (C), 158.4 (d, J = 250.5 Hz, CF), 156.1 (C), 
143.2 (C), 139.0 (d, J = 3.6 Hz, C), 129.7 (CH), 128.2 (d, J = 8.3 Hz, CH), 
120.9 (d, J = 19.2 Hz, C), 120.5 (CH), 118.3 (d, J = 22.7 Hz, CH), 20.8 
(CH3). 
19F NMR (376 MHz, DMSO-d6) δ -113.33 (s). IR (neat):1730.9 (s), 
1621.8 (s), 1470.4 (s), 1415.4 (s), 1265.7 (s), 1220.0 (s), 1063.5 (s), 
1011.6 (s), 892.0 (s), 828.2 (s), 707.9 (s) cm-1. LC-MS (ESI): 281.2 (M-H). 
HRMS (ESI): calculated for C12H9N2O3FCl 283.0286, found 283.0284 
(M+H, Δ = -0.2 mDa). 
1-(2-phenoxyphenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylic acid, 14, 83%. 
Compound description: dark brown solid. Mp: 170.4 - 171.2 °C. 1H NMR 
(400 MHz, DMSO-d6) δ 15.17 (brs, 1H), 7.73 (d, J = 7.8 Hz, 1H), 7.62 (t, 
J = 7.9 Hz, 1H), 7.30 - 7.45 (m, 3H), 7.19 (t, J = 7.4 Hz, 1H), 6.95 - 7.15 
(m, 4H), 2.30 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.1 (C), 163.0 
(C), 156.5 (C), 155.3 (C), 151.9 (C), 143.6 (C), 132.8 (CH), 132.4 (C), 
130.7 (CH), 129.2 (CH), 125.3 (CH), 124.7 (CH), 120.2 (CH), 119.8 (CH), 
119.2 (CH), 20.0 (CH3). IR (neat): 1739.5 (m), 1583.5 (m), 1488.4 (s), 
1451.9 (s), 1235.7 (s), 1021.9 (m), 871.4 (s), 766.3 (s), 690.4 (s) cm-1. 
LC-MS (ESI): 345.1 (M+Na); HRMS (ESI): calculated for C18H15N2O4 
323.1026, found 323.1036 (M+H, Δ = +1 mDa). 
General Procedure for the Preparation of B series derivatives 15-23. 
To a suspension of 2 (500 mg, 1.62 mmol) in MeCN (6 mL), 1,1’-
carbonyldiimidazole (1.9 mmol) was added and the mixture strirred at 
room temperature for 1 h. The appropriate amine (2.4 mmol) was thus 
added and crude reacted for additional 15 h at room temperature. For 
those reactions leading to a substantial precipitation of the desired 
product, the crude mixture was filtered. The solid was washed with 
MeCN (2 mL) and Et2O (2×4 mL) obtaining pure compounds 15-18, 20. 
The filtrate was dryed under vacuum and the residue purified by flash 
chromatography (CH2Cl2/MeOH). Alternatively, in the case of negligible 
precipitation, the crude mixture was diluted with EtOAc (60 mL) and the 
organic washed with HCl 1 M (25 mL), H2O (25 mL) and finally with brine 
(25 mL). The separated organic layer was treated with Na2SO4 and dried 
under reduced pressure. The residue was purified by flash 
chromatography (CH2Cl2/MeOH) affording pure compounds 19, 21-23 in 
yield ranging from 51% to 89%. 
N,1-bis(4-bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxamide, 15, 72 %. 
Compound description: cream solid. Mp: 224.8 - 226.6 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6)
 δ 12.29 (s, 1H), 7.84 (d, J = 8 Hz, 1H), 
7.67 (d, J = 8 Hz, 1H), 7.61 (d, J = 8 Hz, 1H), 7.56 (d, J = 8 Hz, 1H) 6.92 
(s, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.4 (C), 159.9 
(C), 153.7 (C), 145.5 (C), 141.7 (C), 137.9 (C), 133.0 (CH), 132.4 (CH), 
129.2 (2CH), 123.6 (C), 122.2 (2CH), 121.0 (CH), 116.3 (C), 20.6 (CH3). 
IR (neat): 3060.8 (w), 1686.7 (m), 1538.7 (m), 1484.8 (s), 1395.6 (w), 
1069.6 (m), 1008.2 (m), 820.6 (s), 738.01 (m), 586.5 (w) 510.31 (s) cm-1. 
LC-MS (ESI): 461.9 (M+H). HRMS (ESI): calculated for C18H14N3O2Br2 
461.9453, found 461.9451 (M+H, Δ = -0.2 mDa). 
N-phenyl-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-
3-carboxamide, 16a, 87%. 
Compound description: white solid. Mp: 250.7 - 253.1 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 12.24 (s, 1H), 7.84), 7.69 (d, J = 8 Hz, 
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2H), 7.62 (d, J = 8 Hz, 2H), 7.38 (t, J = 8 Hz, 2H), 7.14 (t, J = 8 Hz, 1H), 
6.92 (s, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.5 (C), 
159.7 (C), 153.7 (C), 145.5 (C), 141.8 (C), 138.6 (C), 133.0 (CH), 129.5 
(2CH), 129.2 (2CH), 124.7 (C), 123.6 (CH), 121.0 (CH), 120.2 (CH), 20.6 
(CH3). IR (neat): 3028.4 (w), 1688.1 (s), 1538.8 (m), 1483.7 (m), 1285.7 
(m) 1195.7 (w), 1010.7 (w), 854.4 (m), 760.4 (s), 692.7 (m), 586.7 (m), 
554.8 (s), 509.6 (m) cm-1. LC-MS (ESI): 384.0 (M+H). HRMS (ESI): 
calculated for C18H15N3O2Br 384.0348, found 384.0338 (M+H, Δ = -1.0 
mDa). 
N-(3-bromophenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 16b, 67%. 
Compound description: cream solid. Mp: 207.0 - 209.5 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 12.31 (s, 1H), 8.07 (s, 1H), 7.84 (d, J = 
8 Hz, 2H), 7.61 (d, J = 8 Hz, 2H), 7.57-7.54 (m, 1H), 7.35-7.34 (m, 2H), 
6.93 (s, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 170.3 (C), 
160.1 (C), 153.8 (C), 145.4 (C), 141.7 (C), 140.1 (C), 133.1 (CH), 131.5 
(CH), 129.2 (CH), 127.4 (CH), 123.6 (C), 122.6 (CH), 122.23 (C), 121.1 
(CH), 119.1 (CH), 20.6 (CH3). IR (neat): 2970.6 (w), 1687.37 (m), 1588.7 
(m), 1476.0 (s), 1289.1 (w), 1194.6 (w), 1067.8 (m), 1006.6 (w), 870.21 
(w), 837.7 (s), 766.0 (s), 732.41 (m), 675.0 (m), 561.7 (m), 509.0 (w) cm-1. 
LC-MS (ESI): 461.9 (M+H). HRMS (ESI): calculated for C18H14N3O2Br2 
461.9453, found 461.9455 (M+H, Δ = +0.2 mDa). 
N-(3-chlorophenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 16c, 87%. 
Compound description: off white solid. Mp: 209.8 - 211.6 °C 
(decomposed). 1H NMR (400 MHz, DMSO-d6) δ 12.32 (s, 1H), 7.94 (t, J 
= 1.9 Hz, 1H), 7.84 d, J = 8 Hz, 2H), 7.62 (d, J = 8 Hz, 2H), 7.52 (d, J = 8 
Hz, 1H), 7.41 (d, J = 8 Hz, 1H), 7.20 (d, J = 8 Hz, 1H), 6.93 (s, 1H), 2.22 
(s, CH3). 
13C NMR (101 MHz, DMSO-d6) δ 170.3 (C), 160.1 (C), 153.8(C), 
145.4 (C), 141.7 (C), 139.9 (C), 133.8 (CH), 133.1 (CH), 131.2 (CH), 
129.2 (CH), 124.4 (C), 123.6 (C), 121.1(CH), 119.8 (CH), 118.8 (CH), 
20.6 (CH3). IR (neat): 2934.0 (w), 1695.6 (m), 1592.8 (m), 1547.0 (s), 
1489.8 (m), 1398.9 (w) 1291.4 (w), 1193.6 (w), 1072.4 (m), 864.8 (m), 
813.9 (w), 864.8 (m), 772.6 (s), 731.9 (m), 675.4 (s), 554.1 (s), 506.8 (m) 
cm-1. LC-MS (ESI): 417.8 (M+H). HRMS (ESI): calculated for 
C18H14N3O2ClBr 417.9958, found 417.9960 (M+H, Δ = +0.2 mDa). 
N-(3-fluorophenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 16d, 66%. 
Compound description: cream solid. Mp: 208.2 - 209.9 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 12.35 (s, 1H), 7.84 (d, J = 8 Hz, 2H), 
7.73 (d, J = 8 Hz, 1H), 7.62 (d, J = 8 Hz, 2H), 7.45 - 7.36 (m, 2H), 6.98 (t, 
J = 8 Hz, 1H), 6.93 (s, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) 
δ 170.3 (C), 162.6 (d, J = 241 Hz, CF), 160.1 (C), 153.8 (C), 145.4 (C), 
141.7 (C), 140.2 (d, J = 11 Hz, C), 133.0 (2CH), 131.2 (d, J = 10 Hz, CH), 
129.2 (2CH), 123.6 (C), 121.1 (CH), 116.1 (d, J = 3 Hz, CH), 111.2 (d, J 
= 21 Hz, CH), 107.2 (d, J = 26 Hz, CH), 20.6 (CH3). IR (neat): 3060.6 (w), 
1691.6 (m), 1597.2 (s), 1557.5 (m), 1488.9 (s), 1293.6 (w), 1199.5 (m), 
1142.8 (m), 1015.2 (w), 859.0 (s), 844.3 (s), 781.6 (m), 737.8 (m), 683.0 
(m), 587.5 (m), 564.2 (m), 504.4 (w) cm-1. LC-MS (ESI): 417.8 (M+H). 
HRMS (ESI): calculated for C18H14N3O2FBr 402.0253, found 402.0259 
(M+H, Δ = +0.6 mDa). 
N-(3-methoxyphenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 16e, 78%. 
Compound description: off white solid. Mp: 188.5 - 189.4 °C 
(decomposed). 1H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 7.84 (d, J 
= 8 Hz, 2H), 7.61 (d, J = 8 Hz, 2H), 7.40 (s, 1H), 7.28 (t, J = 8 Hz, 1H) 
7.18 (d, J = 8 Hz, 1H), 6.92, (s, 1H) 6.72 (d J = 8 Hz, 1H), 3.76 (s, 3H), 
2.22 (s, 3H).13C NMR (101 MHz, DMSO-d6) δ 170.5 (C), 160.1 (C), 159.7 
(C), 153.7 (C), 145.4 (C), 141.8 (C), 139.7 (C), 133.0 (CH) , 130.4 (CH), 
129.2 (CH), 123.6 (C), 121.0 (CH), 112.5 (CH), 110.2 (CH), 106.0 (CH), 
55.5 (CH3), 20.6 (CH3). IR (neat): 2967.8 (w), 1683.3 (s), 1597.5 (m), 
1557.7 (s), 1485.7 (m), 1413.6 (w), 1292.1 (w), 1216.7 (s), 1154.4 (m), 
1012.9 (w), 851.6 (w), 815.1 (m), 738.21 (m), 681.8 (m), 626.6 (w), 583.6 
(w), 555.3 (s), 504.9 (w) cm-1. LC-MS (ESI): 411.9 (M-H). HRMS (ESI): 
calculated for C19H17N3O3Br 414.0453, found 414.0457 (M+H, Δ = +0.4 
mDa). 
N-(3-(trifluoromethyl)phenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 16f, 94%. 
Compound description: white solid. Mp: 201.2 - 202.4 °C (decomposed). 
1H NMR (700 MHz, DMSO-d6) δ 12.36 (s, 1H), 8.18 (s 1H), 7.82 (m, 3H), 
7.59 (m, 3H), 7.46 (d, J = 7.7 Hz, 1H), 6.90 (s, 1H), 2.19 (s, 3H). 13C 
NMR (176 MHz, DMSO-d6) δ 170.2 (C), 160.3 (C), 153.8 (C), 145.5 (C), 
141.7 (C), 139.3 (C), 133.0 (CH), 130.8 (CH), 130.1 (q, J = 31.5 Hz, C), 
129.2 (CH), 124.4 (q, J = 272 Hz, CF3), 123.9 (C), 123.6 (CH), 121.05 
(CH), 121.04 (q, J = 4, CH), 116.4 (q, J = 4, CH), 20.6 (CH3). 
19F NMR 
(376 MHz, DMSO) δ -61.35 (s). IR (neat): 2973.0 (w), 1697.41 (m), 
1614.7 (w), 1553.9 (m), 1488.8 (m), 1416.9 (w), 1327.51 (s), 1166.1 (s), 
1123.9 (s), 1069.1 (m), 1014.2 (w), 837.8 (w), 734.22 (m), 695.9 (m), 
588.2 (w), 559.9 (s), 506.05 (w) cm-1. LC-MS (ESI): 452.0 (M+H). HRMS 
(ESI): calculated for C19H14BrF3N3O2 452.0221, found 452.0222 (M+H, Δ 
= +0.1 mDa). 
N-(3-chloro-4-fluorophenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 17, 80%. 
Compound description: off white solid. Mp: 206.1 - 208.5 °C 
(decomposed). 1H NMR (400 MHz, DMSO-d6) δ 12.30 (s, 1H), 8.06 (dd, 
J = 6.4 Hz, 2 Hz, 1H), 7.85 (d, J = 8 Hz, 2H), 7.63-7.58 (m, 3H), 7.43 (t, J 
= 9.2 Hz, 1H), 6.92 (s, 1H), 2.22 (s, 3H). 13C NMR (101 MHz, DMSO-d6) 
δ 170.2 (C), 160.1 (C), 154.1 (d, J = 243 Hz, C), 153.8 (C), 145.4 (C), 
141.7 (C), 135.8 (d, J = 3 Hz, C), 133.0 (CH), 129.2 (CH), 123.6 (C), 
121.8 (CH), 121.1 (CH), 120.8 (d, J = 7.1 Hz, CH), 119.9 (d, J = 18.5 Hz, 
C), 117.7 (d, J = 22 Hz, CH), 20.6 (CH3). 
19F NMR (376 MHz, DMSO) δ -
121.39 (s). IR (neat): 2371.7 (w), 1695.5 (m), 1554.1 (m), 1487.0 (m), 
1399.1 (w), 1212.1 (m), 1006.1 (w), 865.3 (w), 814.7 (m), 732.6 (m), 
691.20 (m), 587.44 (w), 524.5 (s), 493.3 (w) cm-1. LC-MS (ESI): 436.0 
(M+H). HRMS (ESI): calculated for C18H13BrClFN3O2 435.9864, found 
435.9871 (M+H, Δ = +0.7 mDa). 
N-(2-phenoxyphenyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 18, 91%. 
Compound description: white solid. Mp: 253.7 - 254.9 °C (decomposed). 
1H NMR (700 MHz, DMSO-d6) δ 12.91 (s, 1H), 8.51 (d, J = 7.7 Hz, 1H), 
7.81 (d, J = 7.7 Hz, 2H), 7.57 (d, J = 7.7 Hz, 2H), 7.36 (t, J = 7.7 Hz, 2H), 
7.17, (t, J = 7.7 Hz, 1H), 7.13-7.08 (m, 2H), 7.01 (d, J = 7.7 Hz, 2H), 6.97 
(d, J = 7.7 Hz, 1H), 6.85 (s, 1H), 2.15 (s, 3H). 13C NMR (176 MHz, 
DMSO-d6) δ 170.9 (C), 159.3 (C), 157.1 (C), 153.6 (C), 145.9 (C), 143.7 
(C), 141.8 (C), 133.0 (CH), 130.8 (CH), 130.4 (CH), 129.2 (CH), 125.1 
(C), 124.7 (CH), 123.9 (CH), 123.6 (C), 121.7 (CH), 121.4 (CH), 119.5 
(CH), 118.3 (CH), 20.5 (CH3). IR (neat): 3066.3 (w), 1683.2 (m), 1592.3 
(m), 1538.8 (m), 1480.5 (m), 1456.3 (s), 1218.0 (m), 1065.8 (w), 1011.1 
(w), 854.9 (w), 748.1 (s), 737.0 (s), 686.9 (m), 560.6 (w), 508.3 (w) cm-1. 
LC-MS (ESI): 475.9 (M+H). HRMS (ESI): calculated for C24H19BrN3O3 
476.0610, found 476.0603 (M+H, Δ = -0.7 mDa). 
N-cyclohexyl-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 19, 51%. 
Compound description: white solid. Mp: 203.8 - 205.7 °C. 1H NMR (400 
MHz, DMSO-d6) δ 10.06 (d, J = 7.6, 1H), 7.82 (d, J = 8.8, 2H) 7.57 (d, J = 
8.8, 2H), 6.81 (s, 1H), 3.84-3.73 (m, 1H), 2.17 (s, 3H), 1.87 - 1.77 (m, 
2H), , 1.71 - 1.62 (m, 2H), 1.59 - 1.49 (m, 1H), 1.43 - 1.18 (m, 5H). 13C 
NMR (101 MHz, DMSO-d6) δ 170.7 (C), 160.4 (C), 153.1 (C), 145.2 (C), 
141.8 (C), 133.0 (CH), 129.3 (CH), 123.5 (C), 120.8 (CH), 47.7 (CH), 
32.6 (CH2), 25.6 (CH2), 24.5 (CH2), 20.5 (CH3). IR (neat): 2924.4 (m), 
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2850.1 (w), 1738.4 (W), 1684.3 (s), 1616.1 (m), 1527.0 (m), 1495.4 (m), 
1207.4 (m), 1014.9 (m), 866.2 (s), 859.6 (s), 733.6 (m), 691.6 (w), 584.7 
(w), 557.5 (m), 510.7 (m) cm-1. LC-MS (ESI): 390.0 (M+H). HRMS (ESI): 
calculated for C18H21BrN3O2 390.0817, found 390.0824 (M+H, Δ = +0.7 
mDa). 
N-N-(2-(1H-indol-3-yl)ethyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 20, 90%. 
Compound description: off white solid. Mp: 276.5 °C (decomposed). 1H 
NMR (400 MHz, DMSO-d6) δ 10.88 (s, 1H), 10.06 (t, J = 5.6 Hz, 1H), 
7.82 (d, J = 8.4 Hz, 2H), 7.61 - 7.54 (m, 3H), 7.34 (d, J = 8 Hz, 1H), 7.19 
(s, 1H), 7.07 (t, J = 7.6 Hz, 1H), 6.97 (t, J = 7.2 Hz, 1H), 6.79 (s, 1H), 
3.60 (q, J = 6, 2H), 2.94 (t, J = 7.2, 2H), 2.16 (s, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 170.5 (C), 161.5 (C), 153.1 (C), 145.3 (C), 141.8 (C), 136.7 
(C), 133.0 (CH), 129.3 (CH), 127.6 (C), 123.5 (C), 121.4 (CH), 120.8 
(CH), 118.8 (CH), 118.7 (CH), 111.9 (C), 111.8 (CH), 40.0 (CH2), 25.5 
(CH2), 20.5 (CH3). IR (neat): 3254.3 (w), 1665.0 (s), 1612.4 (m), 1530.3 
(m), 1487.0 (m), 1433.7 (w), 1359.8 (w), 1299.64 (w), 1069.0 (w), 
1013.14 (m), 861.7 (m), 748.2 (s), 734.8 (m), 701.4 (m), 584.2 (w), 515.9 
(m) cm-1. LC-MS (ESI): 452.9 (M+2H). HRMS (ESI): calculated for 
C22H20BrN4O2 451.0770, found 451.0762 (M+H, Δ = -0.8 mDa). 
N-benzyl-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-
3-carboxamide, 21, 76%. 
Compound description: off white solid. Mp: 202.4 - 203.9 °C 
(decomposed). 1H NMR (700 MHz, DMSO-d6) δ 7.72 (d, J = 8.4 Hz, 2H), 
7.45 (d, J = 7 Hz, 2H), 7.42 (d, J = 9 Hz, 2H), 7.35 (t, J = 7.7 Hz, 2H), 
7.31 (t, J = 7 Hz, 1H ) 6.33 (s, 1H), 3.94 (s, 2H), 2.07 (s, 3H). 13C NMR 
(176 MHz, DMSO-d6) δ 169.0 (C), 166.2 (C), 151.1 (C), 142.0 (C), 135.7 
(C), 132.7 (CH), 129.3 (CH), 129.1 (CH), 128.9 (CH), 128.5 (CH), 122.5 
(CH), 116.7 (C), 42.9 (CH2), 20.8 (CH3). IR (neat): 3048.7 (w), 1738.3 (w), 
1649.5 (w), 1594.8 (s), 1579.7 (s), 1487.3 (m), 1396.1 (w), 1219.7 (m), 
1068.4 (m), 1011.4 (w), 859.0 (w), 750.2 (m), 700.2 (s), 635.8 (m), 572.0 
(w), 491.5 (m) cm-1. LC-MS (ESI): 397.8 (M+H). HRMS (ESI): calculated 
for C19H17BrN3O2, 398.0504, found 398.0507 (M+H, Δ = +0.3 mDa). 
N-(adamantan-1-yl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 22, 58%. 
Compound description: cream solid. Mp: 258.2 - 259.6 °C. 1H NMR (400 
MHz, DMSO-d6) δ 9.98 (s, 1H), 7.81 (d, J = 8 Hz, 2H), 7.57 (d, J = 8 Hz, 
2H), 6.79 (s, 1H), 2.16 (s, 3H), 2.10-1.94 (m, 9H), 1.66 (s, 6H). 13C NMR 
(101 MHz, DMSO-d6) δ 170.8 (C), 159.9 (C), 153.1 (C), 145.4 (C), 141.8 
(C), 133.0 (CH), 129.3 (CH), 123.5 (C), 120.8 (CH), 51.6 (C), 41.5 (CH2), 
36.4 (CH2), 29.2 (CH, 20.4 (CH3). IR (neat): 3046.5 (w), 2899.0 (m), 
2854.2 (w), 1690.2 (s), 1619.7 (m), 1554.1 (m), 1492.6 (m), 1412.7 (w), 
1358.2 (w), 1214.6 (w), 1064.8 (w), 1016.3 (m), 869.4 (s), 844.2 (m), 
732.6 (m), 695.6 (w), 570.4 (s), 505.9 (m) cm-1. LC-MS (ESI): 442.1 
(M+H). HRMS (ESI): calculated for C22H25BrN3O2, 442.1130, found 
442.1133 (M+H, Δ = +0.3 mDa). 
N-(2-ethylhexyl)-1-(4-bromophenyl)-6-methyl-4-oxo-1,4-
dihydropyridazine-3-carboxamide, 23, 89%. 
Compound description: white solid. Mp: 129.8 - 131.1 °C (decomposed). 
1H NMR (400 MHz, DMSO-d6) δ 10.07 (t, J = 5.6, 1H), 7.82 (d, J = 8.8, 
2H), 7.58 (d, J = 8.8, 2H), 6.81 (s, 2H), 3.32 - 3.21 (m, 2H), 2.17 (s, 3H), 
1.53 - 1.43 (m, 1H), 1.36 - 1.21 (m, 8H), 0.87 (t, J = 7.2, 6H).
 13C NMR 
(101 MHz, DMSO-d6) δ 170.7 (C), 161.5 (C), 153.2 (C), 145.1 (C), 141.8 
(C), 133.0 (CH), 129.3 (CH), 123.5 (C), 120.9 (CH), 41.6 (CH2), 39.2 
(CH), 31.0 (CH2), 28.8 (CH2), 24.4 (CH2), 22.9 (CH2), 20.5 (CH3), 14.4 
(CH3), 11.3 (CH3). IR (neat): 2959.4 (m), 2919.1 (m), 2858.4 (w), 1740.3 
(m), 1677.7 (s), 1612.6 (m), 1538.7 (m), 1486.7 (m), 1464.5 (m), 1415.0 
(m), 1377.9 (w), 1292.9 (w), 1208.8 (w), 1070.7 (w), 1011.8 (w), 867.9 
(w), 735.3 (m), 75.4 (w), 585.5 (w), 512.5 (m) cm-1. LC-MS (ESI): 420.0 
(M+H). HRMS (ESI): calculated for C20H27BrN3O2, 420.1287, found 
420.1285 (M+H, Δ = -0.2 mDa). 
Methyl 1-(4-bromophenyl)-6-methyl-4-oxo-1,4-dihydropyridazine-3-
carboxylate, 24, 82%. 
To a suspension of 2 (10 g, 32.4 mmol) in MeOH (120 mL), H2SO4 95% 
(0.2 mL) was added and the mixture refluxed for 15 h. The crude material 
was concentrated under reduced pressure and the residue diluted with 
CH2Cl2 (150 mL). The resulting solution was washed with NaHCO3 (ss) (50 
ml). The separated organic layer was treated with Na2SO4, filtered and 
dried under vacuum. The crude material was triturated in AcOEt (15-20 
mL) and the suspension obtained was filtered. The solid was washed 
with Et2O and dried yielding 8.6 g of pure titled compound as an off white 
powder. 
Mp: 171.3 - 172.7 °C (decomposed). 1H NMR (400 MHz, DMSO-d6) δ 
7.79 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 6.66 (s, 1H), 3.81 (s, 
3H), 2.13 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 167.5 (C), 163.6 (C), 
152.9 (C), 148.3 (C), 141.4 (C), 133.0 (CH), 129.3 (CH), 123.4 (C), 119.9 
(CH), 53.0 (CH3), 20.8 (CH3). IR (neat): 3027.2 (w), 2591.1 (w), 1739.6 
(s), 1626.8 (m), 1487.0 (w), 1409.4 (w), 1380.2 (w), 1350.5 (w), 1314.3 
(w), 1240.8 (m), 1203.6 (s), 1081.7 (m), 1014.3 (m), 861.4 (m), 848.2 (m), 
798.4 (w), 761.1 (w), 733.3 (m), 713.3 (w), 592.2 (w), 571.0 (w), 513.8 
(m), 473.3 (w), 422.3 (w) cm-1. LC-MS (ESI): 323.5 (M+H). HRMS (ESI): 
calculated for C13H12BrN2O3, 323.0031, found 323.0026 (M+H, Δ = -0.5 
mDa). 
Methyl 1-(4-bromophenyl)-6-methyl-4-thioxo-1,4-dihydropyridazine-
3-carboxylate, 25, 93%. 
To a suspension of 24 (3 g, 9.3 mmol) in toluene (60 mL), Lawesson’s 
reagent (3.75 g, 9.3 mmol) was added and the mixture stirred at room 
temperature for 1 h. The resulting orange suspension was filtered and 
the filtrate dried under vacuum. The residue was dissolved in CH2Cl2 and 
filtered on a silica gel pad (CH2Cl2) obtaining 2.93 g of pure title 
compound as a yellow powder. 
Mp: 166.3 - 167.6 °C (decomposed). 1H NMR (400 MHz, DMSO-d6) δ 
7.82 (d, J = 8.4 Hz, 2H), 7.75 (s, 1H), 7.62 (d, J = 8.4 Hz, 2H), 3.82 (s, 
3H), 2.16 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 180.0 (C), 164.3 (C), 
156.2 (C), 147.9 (C), 141.1 (C), 135.5 (CH), 133.1 (CH), 128.8 (CH), 
123.9 (C), 53.2 (CH3), 20.2 (CH3). IR (neat): 2947.3 (w), 1750.3 (m), 
1736.8 (s), 1567.1 (s), 1485.8 (m), 1436.2 (w), 1401.9 (w), 1273.4 (s), 
1238.0 (m), 1149.4 (m), 1117.8 (s), 1078.2 (s), 1014.9 (s), 938.7 (w), 
843.4 (m), 772.4 (m), 730.6 (w), 629.2 (w), 554.7 (w), 513.9 (w), 441.0 
(w) cm-1. LC-MS (ESI): 339.0 (M+H). HRMS (ESI): calculated for 
C13H12BrN2O2S, 338.9803, found 338.9797 (M+H, Δ = -0.6 mDa). 
5-(4-bromophenyl)-6-methyl-2H-pyrazolo[4,3-c]pyridazin-3(5H)-one, 
26, 78%. 
To a solution of 25 (2 g, 5.9 mmol) in EtOH (50 mL), N2H4 1M in THF 
(11.8 mL, 11.8 mmol) was added and the mixture refluxed for 1 h. The 
resulting black solution was dried under reduced pressure and the 
residue triturated in CH2Cl2 (5-10 mL). The suspension was filtered 
recovering 1.23 g of pure desired product as a dark brown powder. The 
filtrate was dried and purified by flash chromatography (CH2Cl2/MeOH) 
obtaining additional 180 mg of pure title compound. 
Mp: 294.8-295.5 °C. 1H NMR (400 MHz, DMSO-d6) δ 11.92 (s, NH), 7.81 
(d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.19 (s, 1H), 2.17 (s, 3H). 
13C NMR (101 MHz, DMSO-d6) δ 160.9 (C), 143.2 (C), 142.3 (C), 140.9 
(C), 135.7 (C), 132.9 (CH), 129.5 (CH), 123.3 (C), 110.8 (CH), 21.0 (CH3). 
IR (neat): 3299.5 (w), 3252.6 (w), 1659.5 (m), 1609.0 (s), 1564.5 (m) 
1388.4 (w), 1312.3 (w), 1141.2 (w), 1069.7 (w), 1014.4 (w), 846.3 (m), 
779.5 (m), 724.9 (s), 677.1 (m), 582.2 (m), 549.2 (s), 491.0 (w), 415.6 (w) 
cm-1. LC-MS (ESI): 305.1 (M+H). HRMS (ESI): calculated for 
C12H10BrN4O, 305.0038, found 305.0043 (M+H, Δ = +0.5 mDa). 
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General Procedures for the Preparation of C series derivatives 27-31. 
Method A. To a suspension of 25 (200 mg, 0.59 mmol) in EtOH (8 mL), 
the opportune hydrazine (2.4 mmol) was added and crude reacted under 
microwave irradiation at 150 °C for 2 h. In the case when the hydrazine 
was in its hydrochloride salt form, DIPEA (3 mmol) was also added. The 
crude mixture was concentrated and the residue diluted CH2Cl2 (60 mL). 
The resulting solution was washed with HCl 1M (2×30 mL), water and 
brine. The separated organic layer was treated with Na2SO4 and dried 
under reduced pressure. The residue was purified by flash 
chromatography eluting with CH2Cl2/MeOH (27a, 27b, 28a) or 
hexane/AcOEt (27c, 28b) affording pure compounds in yields ranging 
from 35% to 58%. 
Method B. To a 0 °C cooled solution of 26 (200 mg, 0.66 mmol) in DMF 
(8 mL), NaH (60% w/w in paraffin, 0.98 mmol) was added and the 
mixture stirred under N2 atmosfere for 30 min. The appropriate bromo 
derivative was thus added at 0 °C, the crude was slowly heated at 100 °C 
and reacted at this temperature for additional 4 h. After cooling at room 
temperature the resulting solution was diluted with CH2Cl2 (60 mL), 
washed with HCl 1M (4×40 mL), water and brine. The separated organic 
layer was treated with Na2SO4 and dried under reduced pressure. The 
residue was purified by flash chromatography eluting with CH2Cl2/MeOH 
affording pure compounds in yields ranging from 32% to 73%. 
5-(4-bromophenyl)-2-phenyl-6-methyl-2H-pyrazolo[4,3-c]pyridazin-
3(5H)-one, 27a, 57%. 
Compound description: black solid. Mp: 266.1 - 267.4 °C. 1H NMR (400 
MHz, DMSO-d6) δ 8.16 (d, J = 8 Hz, 2H), 7.85 (d, J = 8 Hz, 2H), 7.64 (d, 
J = 8 Hz, 2H), 7.48 (t, J = 8 Hz, 2H), 7.39 (s, 1H), 7.25 (t, J = 8 Hz, 1H), 
2.24 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 157.7 (C), 145.3 (C), 
142.2 (C), 140.7 (C), 139.7 (C), 136.6 (C), 133.0 (CH), 129.5 (CH), 129.4 
(CH), 125.6 (CH), 123.6 (C), 119.2 (CH), 110.5 (CH), 21.2 (CH3). IR 
(neat): 1670.8 (m), 1609.4 (m), 1483.8 (m), 1345.6 (m), 1294.9 (m), 
1219.2 (w), 1147.4 (w), 1100.4 (w), 1064.6 (w), 1008.9 (w), 879.4 (w), 
832.7 (w), 795.8 (w), 765.5 (s), 737.4 (w), 688.5 (s), 635.5 (w), 567.5 (w), 
514.2 (w), 501.9 (w), 444.0 (w), 412.7 (w) cm-1. LC-MS (ESI): 381.1 
(M+H). HRMS (ESI): calculated for C18H14BrN4O, 331.0351, found 
331.0339 (M+H, Δ = -1.2 mDa) 
5-(4-bromophenyl)-2-(3-methoxyphenyl)-6-methyl-2H-pyrazolo[4,3-
c]pyridazin-3(5H)-one, 27b, 52%. 
Compound description: dark brown solid. Mp: 230.7 - 231.5 °C. 1H NMR 
(400 MHz, DMSO-d6) δ 7.85 (d, J = 8 Hz, 2H), 7.82-7.76 (m, 2H), 7.64 (d, 
J = 8 Hz, 2H), 7.40 - 7.36 (m, 2H), 6.85 - 6.82 (m, 1H) 3.81 (s, 3H), 2.24 
(s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 160.0 (C), 157.8 (C), 145.4 (C), 
142.2 (C), 140.8 (C), 140.7 (C), 136.6 (C), 133.0 (CH), 130.2 (CH), 129.5 
(CH), 123.6 (C), 111.4 (CH), 111.2 (CH), 110.4 (CH), 104.8 (CH), 55.7 
(CH3), 21.2 (CH3). IR (neat): 3053.2 (w), 2835.3 (w), 1671.4 (m), 1598.8 
(s), 1566.5 (m), 1482.8 (m), 1429.7 (w), 1349.6 (w), 1313.7 (w), 1296.4 
(w), 1244.3 (s), 1210.0 (w), 1153.5 (m), 1042.3 (m), 1008.2 (w), 88.5 (w), 
846.4 (s), 809.7 (w), 785.4 (s), 719.9 (m), 685.6 (m), 635.6 (w),606.3 (w), 
568.2 (m), 502.1 (m), 415.22 (w) cm-1. LC-MS (ESI): 411.0 (M+H). HRMS 
(ESI): calculated for C19H16BrN4O2, 411.0457, found 411.0456 (M+H, Δ = 
-0.1 mDa) 
5-(4-bromophenyl)-2-(3-chlorophenyl)-6-methyl-2H-pyrazolo[4,3-
c]pyridazin-3(5H)-one, 27c, 35%. 
Compound description: brown solid. Mp: 238.2 - 238.9 °C. 1H NMR (400 
MHz, CDCl3) δ 8.26 (t, J = 2.0 Hz, 1H), 8.22 (dd, J = 8.3, 2.0 Hz, 1H), 
7.72 (d, J = 8.7 Hz, 2H), 7.39 (t, J = 8.1 Hz, 1H), 7.31 (d, J = 8.7 Hz, 2H), 
7.22 (dd, J = 8.0, 2.0 Hz, 1H), 6.96 (s, 1H), 2.29 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 157.8 (C), 143.6 (C), 141.7 (C), 141.1 (C), 140.2 (C), 
135.8 (C), 134.6 (C), 133.0 (CH), 129.9 (CH), 128.2 (CH), 125.5 (CH), 
124.3 (C), 119.5 (CH), 117.4 (CH), 110.2 (CH), 21.6 (CH3). IR (neat): 
3114.5 (w), 1674.9 (s), 1602.7 (s), 1572.2 (m), 1482.2 (m), 1429.1 
(m),1353.15 (m), 1295.02 (m), 1267.11 (w), 1151.8 (w), 1065.9 (w), 
1009.9 (w), 846.7 (w), 832.8 (m), 800.0 (w), 768.6 (m), 751.8 (m), 712.4 
(m), 673.8 (m), 625.9 (w), 568.4 (w), 502.6 (m), 439.9 (w) cm-1. LC-MS 
(ESI): 413.0 (M+H). HRMS (ESI): calculated for C18H13BrClN4O, 
414.9961, found 414.9956 (M+H, Δ = -0.5 mDa). 
5-(4-bromophenyl)-2-(4-methoxyphenyl)-6-methyl-2H-pyrazolo[4,3-
c]pyridazin-3(5H)-one, 28a, 58%. 
Compound description: dark brown solid. Mp: 208.4 - 210.2 °C. 1H NMR 
(700 MHz, DMSO-d6) δ 8.03 (d, J = 9.1 Hz, 2H), 7.81 (d, J = 8.6 Hz, 2H), 
7.60 (d, J = 8.6 Hz, 2H), 7.33 (s, 1H), 7.01 (d, J = 9.1 Hz, 2H), 3.76 (s, 
3H), 2.21 (s, 3H).
 13C NMR (176 MHz, DMSO-d6) δ 157.1 (C), 157.0 (C), 
145.0 (C), 142.2 (C), 140.7 (C), 136.2 (C), 133.1 (C), 133.0 (CH), 129.4 
(CH), 123.5 (C), 120.9 (CH), 114.4 (CH), 110.3 (CH), 55.8 (CH3), 21.1 
(CH3). IR (neat): 3043.5 (w), 2841.2 (w), 1660.2 (m), 1602.4 (m), 1579.0 
(w), 1564.1 (w), 1506.7 (m), 1481.2 (w), 1436.4 (w), 1402.2 (w), 1354.6 
(w), 1294.6 (w), 1249.8 (m), 1220.8 (m), 1181.2 (w), 1149.2 (w), 1103.4 
(w), 1069.4 (w), 1026.8 (m), 1008.3 (w), 894.9 (w), 879.6 (w), 831.0 (s), 
802.2 (s), 735.7 (w), 675.5 (w), 608.4 (m), 555.7 (m), 524.9 (s), 412.5 (w) 
cm-1. LC-MS (ESI): 411.1 (M+H). HRMS (ESI): calculated for 
C19H16BrN4O2, 411.0457, found 411.0446 (M+H, Δ = -1.1 mDa). 
2,5-bis(4-bromophenyl)-6-methyl-2H-pyrazolo[4,3-c]pyridazin-3(5H)-
one, 28b, 56%. 
Compound description: brown solid. Mp: 244.9 - 245.7 °C. 1H NMR (400 
MHz, DMSO-d6) δ 8.15 (d, J = 9.0 Hz, 2H), 7.85 (d, J = 8.7 Hz, 2H), 7.67 
(d, J = 9.0 Hz, 2H), 7.64 (d, J = 8.7 Hz, 2H), 7.40 (s, 1H), 2.25 (s, 3H).
 
13C NMR (101 MHz, DMSO-d6) δ 157.8 (C), 145.6 (C), 142.1 (C), 140.5 
(C), 138.9 (C), 136.9 (C), 133.0 (CH), 132.2 (CH), 129.4 (CH), 123.6 (C), 
120.9 (CH), 117.6 (C), 110.6 (CH), 21.2 (CH3). IR (neat): 1679.4 (w), 
1611.5 (m), 1571.6 (w), 1482.9 (m), 1391.8 (w), 1340.0 (m), 1292.7 (w), 
1215.7 (w), 1143.1 (w), 1068.5 (w), 1003.7 (w), 875.6 (w), 835.6 (s), 
826.0 (s), 795.9 (m), 737.9 (w), 703.8 (m), 623.7 (m), 578.4 (m), 507.5 
(s), 441.7 (w), cm-1. LC-MS (ESI): 459.1 (M+H). HRMS (ESI): calculated 
for C18H13Br2N4O, 458.9456, found 458.9450 (M+H, Δ = -0.6 mDa). 
5-(4-bromophenyl)-2-benzyl-6-methyl-2H-pyrazolo[4,3-c]pyridazin-
3(5H)-one, 29, 70%. 
Compound description: brown solid. Mp: 189.2 - 191.4 °C. 1H NMR (400 
MHz, DMSO-d6) δ 7.83 (d, J = 8.6 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H), 7.42-
7.18 (m, 6H), 5.07 (s, 2H), 2.19 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 
158.2 (C), 144.1 (C), 142.3 (C), 140.2 (C), 138.0 (C), 135.1 (C), 133.0 
(CH), 129.5 (CH), 128.9 (CH), 128.1 (CH), 127.7 (CH), 123.5 (C), 110.4 
(CH), 48.6 (CH2), 21.1 (CH3). IR (neat): 3959.7 (w), 2928.9 (w), 1740.1 
(w), 1665.8 (s), 1607.0 (s), 1585.7 (m), 1492.0 (m), 1383.8 (w), 1373.4 
(w), 1326.7 (w), 1288.7 (w), 1209.3 (w), 1144.5 (w), 1071.3 (w), 1013.7 
(w), 856.8 (w), 863.5 (w), 802.2 (w), 775.6 (w), 720.5 (m), 700.2(s), 617.9 
(w), 538.1 (s), 496.1 (w), 415.5 (w) cm-1. LC-MS (ESI): 395.1 (M+H). 
HRMS (ESI): calculated for C19H16BrN4O, 395.0507, found 395.0516 
(M+H, Δ = +0.9 mDa). 
5-(4-bromophenyl)-2-cyclohexyl-6-methyl-2H-pyrazolo[4,3-
c]pyridazin-3(5H)-one, 30, 32%. 
Compound description: brown solid. Mp: 278.6-279.9 °C. 1H NMR (400 
MHz, CDCl3) δ 7.69 (d, J = 8.6 Hz, 2H), 7.27 (s, 2H), 6.95 (s, 1H), 4.58-
4.95 (m, 1H), 2.27 (s, 3H), 2.00-1.79 (m, 6H), 1.77-1.68 (m, 1H) 1.55-
1.38 (m, 2H), 1.34-1.19 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 157.4 (C), 
142.0 (C), 141.3 (C), 134.0 (C), 132.8 (CH), 128.2 (CH), 124.0 (C), 110.4 
(CH), 53.3 (CH), 31.5 (CH2), 25.6 (CH2), 25.3 (CH2), 21.5 (CH3). IR 
(neat): 3036.8 (w), 2926.1 (w), 2852.4 (w), 1664.5 (s), 1615.7 (s), 1559.5 
(m), 1483.1 (w), 1447.7 (w), 1379.1 (w), 1347.9 (w), 1310.8 (w), 1288.5 
(w), 1208.4 (w), 1142.2 (w), 1069.8 (w), 1011.1 (w), 893.2 (w), 835.8 (m), 
794.9 (w), 733.7 (w), 712.7 (w), 693.21 (w), 660.6 (w), 655.1 (w), 624.5 
(w), 569.7 (w), 491.8 (w), 451.6 (w) cm-1. LC-MS (ESI): 409.1 (M+Na). 
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HRMS (ESI): calculated for C18H20BrN4O, 387.0820, found 387.0826 
(M+H, Δ = +0.6 mDa). 
5-(4-bromophenyl)-2-(2-ethylhexyl)-6-methyl-2H-pyrazolo[4,3-
c]pyridazin-3(5H)-one, 31, 73%. 
Compound description: brown solid. Mp: 99.8 - 102.3 °C. 1H NMR (700 
MHz, DMSO-d6) δ 7.86 (d, J = 7.6 Hz, 2H), 7.65 (d, J = 7.8 Hz, 2H), 7.29 
(s, 1H), 3.84-3.72 (m, 2H), 2.24 (s, 3H), 1.95-1.85 (m, 1H), 1.41-1.20 (m, 
8H), 0.90 (s, 6H). 13C NMR (101 MHz, DMSO-d6) δ 158.2 (C), 143.7 (C), 
142.3 (C), 140.4 (C), 134.6 (C), 133.0 (CH), 129.5 (CH), 123.4 (C), 110.2 
(CH), 48.1 (CH2), 38.8 (CH), 30.5 (CH2), 28.5 (CH2), 23.8 (CH2), 22.9 
(CH2), 21.1 (CH3), 14.4 (CH3), 10.9 (CH3). IR (neat): 2956.3 (w), 2930.2 
(w), 2870.7 (w), 1666.6 (s), 1606.0 (s), 1584.5 (w), 1485.5 (w), 1375.0 
(w), 1279.6 (w), 1208.6 (w), 1167.2 (w), 1142.14 (w), 1066.6 (w), 1010.8 
(m), 842.4 (m), 803.0 (w), 722.9 (w), 691.3 (m), 619.4 (w), 505.0 (w), 
463.2 (w), 417.1 (w) cm-1. LC-MS (ESI): 439.1 (M+Na). HRMS (ESI): 
calculated for C20H26BrN4O, 417.1290, found 417.1291 (M+H, Δ = 0.1 
mDa). 
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